vs
Side-by-side financial comparison of Applied Materials (AMAT) and Regeneron Pharmaceuticals (REGN). Click either name above to swap in a different company.
Applied Materials is the larger business by last-quarter revenue ($7.9B vs $3.6B, roughly 2.2× Regeneron Pharmaceuticals). Applied Materials runs the higher net margin — 35.5% vs 20.2%, a 15.3% gap on every dollar of revenue. On growth, Regeneron Pharmaceuticals posted the faster year-over-year revenue change (19.0% vs 11.0%). Over the past eight quarters, Applied Materials's revenue compounded faster (8.0% CAGR vs 0.8%).
Applied Materials, Inc. is an American corporation that supplies equipment, services and software for the manufacture of semiconductor chips for electronics, flat panel displays for computers, smartphones, televisions, and solar products. The company also supplies equipment to produce coatings for flexible electronics, packaging and other applications. The company is headquartered in Santa Clara, California, and is the second largest supplier of semiconductor equipment in the world based on r...
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.
AMAT vs REGN — Head-to-Head
Income Statement — Q3 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $7.9B | $3.6B |
| Net Profit | $2.8B | $727.0M |
| Gross Margin | 49.9% | 89.6% |
| Operating Margin | 26.4% | 17.8% |
| Net Margin | 35.5% | 20.2% |
| Revenue YoY | 11.0% | 19.0% |
| Net Profit YoY | 31.0% | -10.1% |
| EPS (diluted) | $3.51 | $6.75 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 26 | $7.9B | — | ||
| Q1 26 | $7.0B | $3.6B | ||
| Q4 25 | $6.8B | $3.9B | ||
| Q3 25 | $7.3B | $3.8B | ||
| Q2 25 | $7.1B | $3.7B | ||
| Q1 25 | $7.2B | $3.0B | ||
| Q4 24 | $7.0B | $3.8B | ||
| Q3 24 | $6.8B | $3.7B |
| Q2 26 | $2.8B | — | ||
| Q1 26 | $2.0B | $727.0M | ||
| Q4 25 | $1.9B | $844.6M | ||
| Q3 25 | $1.8B | $1.5B | ||
| Q2 25 | $2.1B | $1.4B | ||
| Q1 25 | $1.2B | $808.7M | ||
| Q4 24 | $1.7B | $917.7M | ||
| Q3 24 | $1.7B | $1.3B |
| Q2 26 | 49.9% | — | ||
| Q1 26 | 49.0% | 89.6% | ||
| Q4 25 | 48.0% | — | ||
| Q3 25 | 48.8% | — | ||
| Q2 25 | 49.1% | — | ||
| Q1 25 | 48.8% | — | ||
| Q4 24 | 47.3% | — | ||
| Q3 24 | 47.3% | — |
| Q2 26 | 26.4% | — | ||
| Q1 26 | 20.4% | 17.8% | ||
| Q4 25 | 25.2% | 22.7% | ||
| Q3 25 | 30.6% | 27.3% | ||
| Q2 25 | 30.5% | 29.4% | ||
| Q1 25 | 30.4% | 19.5% | ||
| Q4 24 | 29.0% | 26.1% | ||
| Q3 24 | 28.7% | 31.7% |
| Q2 26 | 35.5% | — | ||
| Q1 26 | 28.9% | 20.2% | ||
| Q4 25 | 27.9% | 21.7% | ||
| Q3 25 | 24.4% | 38.9% | ||
| Q2 25 | 30.1% | 37.9% | ||
| Q1 25 | 16.5% | 26.7% | ||
| Q4 24 | 24.6% | 24.2% | ||
| Q3 24 | 25.2% | 36.0% |
| Q2 26 | $3.51 | — | ||
| Q1 26 | $2.54 | $6.75 | ||
| Q4 25 | $2.36 | $7.78 | ||
| Q3 25 | $2.22 | $13.62 | ||
| Q2 25 | $2.63 | $12.81 | ||
| Q1 25 | $1.45 | $7.27 | ||
| Q4 24 | $2.09 | $8.12 | ||
| Q3 24 | $2.05 | $11.54 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.2B | — |
| Total DebtLower is stronger | $6.5B | $2.0B |
| Stockholders' EquityBook value | $23.9B | $31.4B |
| Total Assets | $40.3B | $40.9B |
| Debt / EquityLower = less leverage | 0.27× | 0.06× |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | $8.2B | — | ||
| Q1 26 | $8.5B | — | ||
| Q4 25 | $8.6B | $8.6B | ||
| Q3 25 | $7.0B | $8.4B | ||
| Q2 25 | $6.7B | $7.5B | ||
| Q1 25 | $8.2B | $8.3B | ||
| Q4 24 | $9.5B | $9.0B | ||
| Q3 24 | $9.1B | $9.8B |
| Q2 26 | $6.5B | — | ||
| Q1 26 | $6.6B | $2.0B | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — |
| Q2 26 | $23.9B | — | ||
| Q1 26 | $21.7B | $31.4B | ||
| Q4 25 | $20.4B | $31.3B | ||
| Q3 25 | $19.5B | $31.0B | ||
| Q2 25 | $19.0B | $29.9B | ||
| Q1 25 | $18.6B | $29.4B | ||
| Q4 24 | $19.0B | $29.4B | ||
| Q3 24 | $18.8B | $29.3B |
| Q2 26 | $40.3B | — | ||
| Q1 26 | $37.6B | $40.9B | ||
| Q4 25 | $36.3B | $40.6B | ||
| Q3 25 | $34.2B | $40.2B | ||
| Q2 25 | $33.6B | $38.2B | ||
| Q1 25 | $33.3B | $37.5B | ||
| Q4 24 | $34.4B | $37.8B | ||
| Q3 24 | $33.6B | $37.4B |
| Q2 26 | 0.27× | — | ||
| Q1 26 | 0.30× | 0.06× | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $1.1B |
| Free Cash FlowOCF − Capex | — | $848.3M |
| FCF MarginFCF / Revenue | — | 23.5% |
| Capex IntensityCapex / Revenue | 8.0% | 6.4% |
| Cash ConversionOCF / Net Profit | — | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | — | $4.1B |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | — | — | ||
| Q1 26 | — | $1.1B | ||
| Q4 25 | $2.8B | $1.2B | ||
| Q3 25 | $2.6B | $1.6B | ||
| Q2 25 | $1.6B | $1.1B | ||
| Q1 25 | $925.0M | $1.0B | ||
| Q4 24 | $2.6B | $1.3B | ||
| Q3 24 | $2.4B | $1.3B |
| Q2 26 | — | — | ||
| Q1 26 | — | $848.3M | ||
| Q4 25 | $2.0B | $922.0M | ||
| Q3 25 | $2.0B | $1.4B | ||
| Q2 25 | $1.1B | $925.4M | ||
| Q1 25 | $544.0M | $815.8M | ||
| Q4 24 | $2.2B | $1.1B | ||
| Q3 24 | $2.1B | $1.0B |
| Q2 26 | — | — | ||
| Q1 26 | — | 23.5% | ||
| Q4 25 | 30.0% | 23.7% | ||
| Q3 25 | 28.1% | 37.8% | ||
| Q2 25 | 14.9% | 25.2% | ||
| Q1 25 | 7.6% | 26.9% | ||
| Q4 24 | 30.8% | 28.1% | ||
| Q3 24 | 30.8% | 28.2% |
| Q2 26 | 8.0% | — | ||
| Q1 26 | 9.2% | 6.4% | ||
| Q4 25 | 11.5% | 6.4% | ||
| Q3 25 | 8.0% | 5.4% | ||
| Q2 25 | 7.2% | 6.0% | ||
| Q1 25 | 5.3% | 7.6% | ||
| Q4 24 | 5.8% | 5.3% | ||
| Q3 24 | 4.4% | 6.5% |
| Q2 26 | — | — | ||
| Q1 26 | — | 1.48× | ||
| Q4 25 | 1.49× | 1.39× | ||
| Q3 25 | 1.48× | 1.11× | ||
| Q2 25 | 0.74× | 0.82× | ||
| Q1 25 | 0.78× | 1.29× | ||
| Q4 24 | 1.49× | 1.38× | ||
| Q3 24 | 1.40× | 0.96× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMAT
Segment breakdown not available.
REGN
| Sanofi | $1.6B | 45% |
| Other | $507.0M | 14% |
| EYLEA - U.S | $473.0M | 13% |
| Bayer | $287.0M | 8% |
| Libtayo ® - U.S | $286.0M | 8% |
| Other revenue | $171.0M | 5% |
| Libtayo - ROW* | $152.0M | 4% |
| Praluent - U.S | $67.0M | 2% |
| Evkeeza ® - U.S | $46.0M | 1% |
| Lynozyfic ® - Global | $11.0M | 0% |
